The national institute for health and care excellence (NICE) of the England has rejected sanofi’s migraine treatment drug aimovig.
The cost effectiveness watchdog cited the inability of the company to supply sufficient evidence to demonstrate that aimovig (erenumab) is more effective than botulinum toxin type A, and that the data presented doesn’t fully reflect what is obtainable in clinical practice in the NHS.
The drug, erenumab, sold as Aimovig in the United States of America by Novartis and partner Amgen, forms part of a new crop of biologics targeting the CGRP protein that transmits pain signals into the brain, and is considered instrumental in generating and maintaining headaches associated with migraine. Aimovig costs around £5,000 (about $6368) per year, excluding a confidential discount that would have been granted to England’s national health service (NHS) had NICE recommended the drug.
NICE’s director of the centre for health technology evaluation Meindert Boysen in a statement,said “There was not enough evidence to suggest that it (erenumab) is more effective than botulinum toxin type A (Allergan’s Botox) for people with chronic migraine, which NICE already recommends. And for both the chronic and episodic migraine populations there was no evidence to show that erenumab is effective in the long-term in people for whom 3 previous preventive treatments had failed